The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | Real-world practical and psychological barriers to lung cancer screening
David Baldwin, MD, FRCP, Nottingham City Hospital, Nottingham, United Kingdom, provides an overview of barriers to lung cancer screening in clinical trials and the real-world. Practical barriers, such as cost and comorbidities, as well as psychological barriers related to the potential diagnosis, can hinder patient participation. Local, community-led programs, staffed by individuals who have personal experience with lung cancer, are crucial in overcoming these barriers and achieving high uptake rates, as seen in the UK’s lung screening program. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, interestingly, barriers have been examined in clinical trials, but clinical trial entry is slightly different from the barriers that people face in real-world screening. Even when they’re not randomised trials, it’s different. But we do know that practical barriers, the cost of travelling, the time that it takes, other things like comorbidities can be barriers to patients, that the psychological risk of actually gaining some knowledge that they didn’t want to know before and the fear of that knowledge is also a barrier...
Yeah, interestingly, barriers have been examined in clinical trials, but clinical trial entry is slightly different from the barriers that people face in real-world screening. Even when they’re not randomised trials, it’s different. But we do know that practical barriers, the cost of travelling, the time that it takes, other things like comorbidities can be barriers to patients, that the psychological risk of actually gaining some knowledge that they didn’t want to know before and the fear of that knowledge is also a barrier. So we know that we can try to mitigate these, but as I said, the lung screening uptake trial didn’t really show any important benefit from trying to mitigate those fears. And when you look at the practical programme, we do see some remarkably different uptake rates of offers. And one of the things that I think is very important in the British programme is the fact that the programmes are run by local people from the local population who speak the local dialect and are generally very passionate about getting patients into the programme because they’ve probably experienced lung cancer in their own lives. And this is probably the key to getting over those barriers, having people on the ground that really believe in the intervention of lung cancer screening, getting involved. And we’ve seen some amazing results in the UK as a result of that.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
